In a filing, Intellia Therapeutics Inc revealed its Director Bhanji Muna unloaded Company’s shares for reported $2642.0 on Jan 29 ’25. In the deal valued at $9.97 per share,265 shares were sold. As a result of this transaction, Bhanji Muna now holds 19,468 shares worth roughly $0.2 million.
Then, Dube Michael P sold 1,372 shares, generating $16,711 in total proceeds. Upon selling the shares at $12.18, the VP, Chief Accounting Officer now owns 45,640 shares.
Before that, BASTA JAMES sold 7,074 shares. Intellia Therapeutics Inc shares valued at $86,161 were divested by the EVP, General Counsel at a price of $12.18 per share. As a result of the transaction, BASTA JAMES now holds 74,497 shares, worth roughly $0.77 million.
Morgan Stanley downgraded its Intellia Therapeutics Inc [NTLA] rating to an Equal-weight from a an Overweight in a research note published on January 27, 2025; the price target was decreased to $11 from $56. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in late February from “a Buy” to “a Neutral”. Wolfe Research began covering NTLA with “Peer perform” recommendation on February 15, 2024. Canaccord Genuity started covering the stock on April 13, 2023. It rated NTLA as “a Buy”.
Price Performance Review of NTLA
On Friday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -1.81% to $10.32. Over the last five days, the stock has lost -6.10%. Intellia Therapeutics Inc shares have fallen nearly -11.49% since the year began. Nevertheless, the stocks have fallen -58.03% over the past one year. While a 52-week high of $34.87 was reached on 01/07/25, a 52-week low of $9.25 was recorded on 01/16/25. SMA at 50 days reached $12.44, while 200 days put it at $19.57.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 10.07, which if violated will result in even more drops to 9.82. On the upside, there is a resistance level at 10.61. A further resistance level may holdings at 10.90. The Relative Strength Index (RSI) on the 14-day chart is 41.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.58%. Stochastics %K at 44.81% indicates the stock is a holding.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-01-15, growing by 4.25 million shares to a total of 24.06 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 19.81 million shares. There was a rise of 17.68%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 21, 2023 when Bernstein began covering the stock and recommended ‘”an Outperform”‘ rating along with a $54 price target.
